The FIGHT-RP1 Study
clinical trial
Press Enter · cited answer in seconds
0 sources
The FIGHT-RP1 Study
Summary
The FIGHT-RP1 Study is a clinical trial[1].
Key Facts
- The FIGHT-RP1 Study is in the country of United States[2].
- The FIGHT-RP1 Study's instance of is recorded as clinical trial[3].
- The FIGHT-RP1 Study's start time is recorded as +2017-02-15T00:00:00Z[4].
- The FIGHT-RP1 Study's end time is recorded as +2019-02-11T00:00:00Z[5].
- The FIGHT-RP1 Study's sponsor is recorded as Johns Hopkins University[6].
- The FIGHT-RP1 Study's main subject is recorded as retinitis pigmentosa[7].
- The FIGHT-RP1 Study's main subject is recorded as retinitis[8].
- The FIGHT-RP1 Study's number of participants is recorded as {'unit': '1', 'amount': '+30'}[9].
- The FIGHT-RP1 Study's title is recorded as A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study)[10].
- The FIGHT-RP1 Study's short name is recorded as FIGHT-RP1[11].
- The FIGHT-RP1 Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[12].
- The FIGHT-RP1 Study's ClinicalTrials.gov ID is recorded as NCT03063021[13].
- The FIGHT-RP1 Study's research intervention is recorded as N-acetyl-L-cysteine[14].
- The FIGHT-RP1 Study's research intervention is recorded as N-monoacetylcystine[15].
- The FIGHT-RP1 Study's clinical trial phase is recorded as phase I clinical trial[16].
- The FIGHT-RP1 Study's research subject recruitment status is recorded as completed[17].
- The FIGHT-RP1 Study's study type is recorded as interventional study[18].